ArticleBritish journal of pharmacology2003
A role of protein kinase C mu in signalling from the human adenosine A1 receptor to the nucleus.
Article in British journal of pharmacology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 9 citations in OpenAlex.
- Adenosine A1 receptors link to smooth muscle contraction via CYP4a, protein kinase C-α, and ERK1/2.Journal of cardiovascular pharmacology · 2013Article
- CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex.Immunity · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
1 Stimulation of adenosine A(1) receptors produced a stimulation of c-fos promoter-regulated gene transcription in Chinese hamster ovary (CHO)-A1 cells expressing the human A(1) receptor. Gene transcription was monitored using a luciferase-based reporter gene (pGL3). 2 This response to the A(1) receptor agonist N(6)-cyclopentyladenosine (CPA) was sensitive to inhibition by pertussis toxin, the MEK-1 inhibitor PD 98059 and by the phosphatidylinositol-3-kinase inhibitors wortmannin and LY 294002. The response was also completely abolished by the protein kinase C (PKC) inhibitor Ro-31-8220. 3 Several isoforms of PKC can be detected in CHO-A1 cells (alpha, delta, epsilon, micro, iota, zeta), but only PKC alpha, PKC delta and PKC were downregulated by prolonged treatment with phorbol ester. The c-fos-regulated luciferase response to A(1) agonists was not, however, inhibited by 24 h pretreatment with the phorbol esters phorbol 12,13-dibutyrate (PDBu). This observation, together with the fact that a significant attenuation (40%) of the c-fos-luciferase response to PDBu and A(1) agonist was produced by low concentrations of the PKC inhibitor Gö 6976 suggests a role for PKC micro. 4 Stimulation of CHO-A1 cells with CPA stimulated the activation of endogenous PKC micro as measured by autophosphorylation. This was rapid, occurred within 1-2 min, but returned to basal levels after 30 min. Furthermore, transient expression of a constitutively active form of PKC micro resulted in a significant increase in c-fos-regulated gene expression. 5 Taken together, these data suggest that PKC micro plays an important role in the ability of the adenosine A(1) receptor to signal to the nucleus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.